Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2017 June;42(2) > Minerva Endocrinologica 2017 June;42(2):145-50

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  ENDOCRINE AND METABOLIC DISORDERS INTERPLAYING WITH NON-ALCOHOLIC FATTY LIVER DISEASE 

Minerva Endocrinologica 2017 June;42(2):145-50

DOI: 10.23736/S0391-1977.16.02570-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Hypogonadism and non-alcoholic fatty liver disease

Gesthimani MINTZIORI, Pavlos POULAKOS, Christos TSAMETIS, Dimitrios G. GOULIS

Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University, Thessaloniki, Greece


PDF


Non-alcoholic fatty liver disease (NAFLD) is more common in men than in women. Thus, it has been suggested that sex steroids do have a role in the development of NAFLD. The aim of the current paper is to illustrate the association between NAFLD and hypogonadism, by reviewing data derived from both human and animal studies. The prevalence of NAFLD is high in men with hypogonadism, including those with idiopathic hypogonadotropic hypogonadism (IHH), as well as in women in post-menopause, those under estrogen receptor antagonist treatment or women with Turner syndrome. Estrogens seem to play a pivotal role in hepatic lipid homeostasis, as demonstrated in animal models with diminished ovarian estrogens (i.e., ovariectomized mice) and low serum testosterone (T) concentration is independently associated with NAFLD. The elucidation of the exact role of sex steroids in NAFLD pathogenesis would create a unique opportunity to develop novel therapies to tackle NAFLD disease.


KEY WORDS: Non-alcoholic fatty liver disease - Hypogonadism - Fatty liver - Testosterone - Estradiol

top of page